

2/24/2023

CURRICULUM VITAE
The Johns Hopkins University School of Medicine

Evan Martin Bloch, MD, MS

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments

University

2019-present Associate Professor, Department of Pathology, Johns Hopkins University School of Medicine
2018-present Director, Post-graduate Fellowship Blood Banking/Transfusion Medicine

Hospital

2015-present Attending Physician, Johns Hopkins Hospital
2015-present Associate Director, Transfusion Medicine division
2021-present Medical Director, Hemapheresis and Transfusion Service
2022-present Physician Advisor, Department of Pathology

Other

2017-present Joint appointment, International Health, Johns Hopkins Bloomberg School of Public Health
2018-present Member, Blood Products Advisory Committee, US Federal Drug Administration

Personal Data

Division of Transfusion Medicine
Department of Pathology
Carnegie 446D1
600 N. Wolfe Street
Baltimore, MD 21287

Tel: 410-614-4246
E-mail: ebloch2@jhmi.edu

Education and Training

1999 MBChB/ Bachelor of Medicine and Bachelor of Surgery, University of Cape Town, Cape Town, ZA
2008 Post-graduate residency in Anatomic and Clinical Pathology, Tufts University, Boston, MA
2009 Post-graduate fellowship in Transfusion Medicine, University of California San Francisco, CA
2010 MS, Global Health, University of California San Francisco, San Francisco, CA

Professional Experience

Date	Position, Institution/City
2000	Intern*, Conradie Hospital, Pinelands, ZA
2001	Senior House Officer (SHO)**, Vredenberg Hospital, Vredenberg, ZA
2002	Resident Medical Officer, St Albans City Hospital, Hertfordshire Trust, UK
2003	SHO Hematology-Oncology, Groote Schuur Hospital, Cape Town, ZA
2003-2004	Locum SHO †Queen Alexandra/St. Mary's Hospital, Portsmouth, UK Withybush General Hospital, Haverfordwest, Wales Princess of Wales Hospital, Bridgend, Wales

2004-2008	Resident, Pathology, Tufts Medical Center, Boston, MA
2008-2009	Fellow, Transfusion Medicine, University of California, San Francisco (UCSF), San Francisco, CA
2009-2010	Masters student (MS-Global Health), UCSF, San Francisco, CA
2010-2015	Assistant Medical Director, Blood Centers of the Pacific, San Francisco, CA
2012-2015	Assistant Adjunct Professor, Laboratory Medicine, UCSF, San Francisco, CA
2013-2015	Associate Clinical Investigator, Blood Systems Research Institute, San Francisco, CA
2015-2019	Assistant Professor, Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
2015-present	Associate Director, Transfusion Medicine, Johns Hopkins Hospital, Baltimore, MD
2017-present	Joint appointment, International Health, Johns Hopkins Bloomberg School of Public Health
2019-present	Associate Professor, Department of Pathology, Johns Hopkins University School of Medicine
2020-2021	Interim Director, Hemapheresis and Transfusion Service, Johns Hopkins Hospital
2021-present	Medical Director, Hemapheresis and Transfusion Service, Johns Hopkins Hospital

PUBLICATIONS:

Original Research [OR]

1. **Bloch EM**, Reed WF, Lee TH, Montalvo L, Shiboski S, Custer B, Barcellos LF. Male microchimerism in peripheral blood leukocytes from women with multiple sclerosis. *Chimerism* 2011;2: 6-10.
2. Mackay G, House M, **Bloch EM**, Wolfberg A. A GBS culture collected shortly after GBS prophylaxis may be inaccurate. *J Matern Fetal Neonatal Med* 2011;25: 736-8.
3. Diané MK, Dembele B, N'Goran L, Konaté S, **Bloch EM**, Murphy E, Lefrère JJ. The Reasons of Blood Donation Deferral in Subsaharan Africa: Experience of Ivory Coast. *Transfusion* 2012;52: 1602-6.
4. **Bloch EM**, Lee TH, Krause PJ, Telford SR 3rd, Montalvo L, Chafets D, Usmani-Brown S, Lepore TJ, Busch MP. Development of a real-time polymerase chain reaction assay for sensitive detection and quantitation of *Babesia microti* infection. *Transfusion* 2013;53: 2299-306.
5. Levin AE, Williamson PC, Erwin JL, Cyrus S, **Bloch EM**, Shaz BH, Kessler D, Telford III SR, Krause P, Wormser GP, Ni X, Wang H, Krueger NX, Caglioti S, Busch MP. Determination of *Babesia microti* Seroprevalence in Blood Donor Populations using an Investigational Enzyme Immunoassay. *Transfusion* 2014; 54: 2237-44.
6. **Bloch EM**, Cohn C, Bruhn R, Hirschler N, Nguyen KA. A cross-sectional pilot study of blood utilization in 27 hospitals in Northern California. *Am J Clin Pathol* 2014; 142(4): 498-505.
7. **Bloch EM**, Busch MP, Lee TH, Montalvo L, Matthews Y, Bird A, Bruhn R, Stefan V. Microchimerism in the Transfused Obstetric Population. *Vox Sang* 2014;107: 428-30.
8. Goodell AJ, **Bloch EM**, Krause PJ, Custer B. Costs, consequences, and cost-effectiveness of strategies for *Babesia microti* donor screening of the US blood supply. *Transfusion* 2014;54: 2245-57.
9. **Bloch EM**, Shah A, Kaidarova Z, Laperche S, Lefrère JJ, van Hasselt J, Zacharias P, Murphy EL. A pilot external quality assurance study of transfusion screening for HIV, HCV and HBsAG in 12 African countries. *Vox Sang* 2014;107: 333-42. [SI/QI]
10. **Bloch EM**, Crookes RL, Hull J, Fawcus S, Gangaram R, Anthony J, Ingram C, Ngcobo S, Croxford J, Creel DV, Murphy EL, International Component of the NRE, Donor Evaluation S, III. The impact of human immunodeficiency virus infection on obstetric hemorrhage and blood transfusion in South Africa. *Transfusion* 2015;55: 1675-84.
11. Kane MA, **Bloch EM**, Bruhn R, Kaidarova Z and Murphy EL. Demographic Determinants of Syphilis Seroprevalence among U.S. Blood Donors, 2011-2012: A Retrospective Data Analysis. *BMC Infect Dis* 2015; 15: 63
12. Muthivhi TN, Olmsted MG, Park H, Sha M, Raju V, Mokoena T, **Bloch EM**, Murphy EL, Reddy R. Motivators and Deterrents to Blood Donation among Black South Africans: A Qualitative Analysis of Focus Group Data. *Transfus Med* 2015; 25(4): 249-58
13. Prugger C, Laperche S, Murphy EL, **Bloch EM**, Kaidarova Z, Tafflet M, Lefrère JJ, Jouven X. Screening for Transfusion Transmissible Infections using Rapid Diagnostic Tests in Africa: a Potential Hazard to Blood Safety? *Vox Sang* 2016; 110(2): 196-8. [SI/QI]
14. Vo MT, Bruhn R, Kaidarova Z, Custer BS, Murphy EL, **Bloch EM**. A Retrospective Analysis of False Positive Infectious Screening Results In Blood Donors. *Transfusion* 2016; 56(2): 457-65.
15. Goodell AJ, **Bloch EM**, Simon MS, H Shaz BH, Custer B. *Babesia* Screening: The Importance of Reporting and Calibration in Cost-Effectiveness Models. *Transfusion* 2016; 56(3): 774-5.
16. **Bloch EM**, Levin AE, Williamson PC, Cyrus S, Shaz BH, Kessler D, Gorlin J, Bruhn R, Lee TH, Montalvo L, Kamel H, Busch MP. A prospective evaluation of chronic *Babesia microti* infection in seroreactive blood donors. *Transfusion* 2016;56: 1875-82.

17. Levin AE, Williamson PC, **Bloch EM**, Clifford J, Cyrus S, Shaz BH, Kessler D, Gorlin J, Erwin JL, Krueger NX, Williams GV, Penezina O, Telford SRt, Branda JA, Krause PJ, Wormser GP, Schotthoefer AM, Fritsche TR, Busch MP. Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay. *Transfusion* 2016;56: 1866-74.
18. Van den Berg K, **Bloch EM**, Aku AS, Mabenge M, Creel DV, Hofmeyr GJ, Murphy EL. A cross-sectional study of peripartum blood transfusion in the Eastern Cape, South Africa. *S Afr Med J* 2016;106: 1103-9.
19. Brooks T, Roy-Burman A, Tuholske C, Busch MP, Bakkour S, Stone M, Linnen JM, Gao K, Coleman J, **Bloch EM**. Evolution of Zika virus outbreak on Roatán, Honduras: A real-time observation of the epidemic. *Emerg Infect Dis* 2017;23.
20. **Bloch EM**, West SK, Mabula K, Weaver J, Mrango Z, Munoz B, Lietman TM, Coles CL Antibiotic resistance in young children in Kilosa district, Tanzania four years after mass distribution of azithromycin for trachoma control. *Am J Trop Med Hygiene* 2017;97: 815-8
21. Vermeulen M, Swanevelder R, Chowdhury D, Ingram C, Reddy R, **Bloch EM**, Custer BS, Murphy EL, Recipient Epidemiology Donor evaluation Study III. Use of Blood Donor Screening to Monitor Prevalence of HIV and Hepatitis B and C Viruses, South Africa. *Emerg Infect Dis* 2017;23: 1560-3.
22. Patel EU, Ness PM, Marshall CE, Gniadek T, Efron DT, Miller PM, Zeitouni JA, King KE, **Bloch EM**, Tobian AAR. Blood Product Utilization Among Trauma and Nontrauma Massive Transfusion Protocols at an Urban Academic Medical Center. *Anesth Analg* 2017;125: 967-74.
23. Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, Kalua K, Mrango Z, Ray KJ, Cook C, Lebas E, O'Brien KS, Emerson PM, Porco TC, Lietman TM; **MORDOR Study Group**. Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. *N Engl J Med*. 2018 Apr 26;378(17):1583-1592.
24. **Bloch EM**, Yang Y, He M, Tonnetti L, Liu Y, Wang J, Guo Y, Li H, Leiby DA, Shan H, Parasite Subgroup International Society of Blood Transfusion Infectious Disease Working Party. A pilot serosurvey of Babesia microti in Chinese blood donors. *Vox Sang* 2018;113: 345-9.
25. **Bloch EM**, Kasubi M, Levin A, Mrango Z, Weaver J, Munoz B, West SK. Babesia microti and Malaria Infection in Africa: A Pilot Serosurvey in Kilosa District, Tanzania. *Am J Trop Med Hyg* 2018;99: 51-6.
26. Theze J, Li T, du Plessis L, Bouquet J, Kraemer MUG, Somasekar S, Yu G, de Cesare M, Balmaseda A, Kuan G, Harris E, Wu CH, Ansari MA, Bowden R, Faria NR, Yagi S, Messenger S, Brooks T, Stone M, **Bloch EM**, Busch M, Munoz-Medina JE, Gonzalez-Bonilla CR, Wolinsky S, Lopez S, Arias CF, Bonsall D, Chiu CY, Pybus OG. Genomic Epidemiology Reconstructs the Introduction and Spread of Zika Virus in Central America and Mexico. *Cell Host Microbe* 2018;23: 855-64 e7.
27. Brissett DI, Tuholske C, Allen IE, Larios NS, Mendoza DJ, Murillo AG, **Bloch EM**. Zika Virus: Knowledge Assessment of Residents and Health-Care Providers in Roatan, Honduras, following an Outbreak. *Am J Trop Med Hyg* 2018;99: 211-5.
28. **Bloch EM**, Marshall CE, Boyd JS, Shifflett L, Tobian AAR, Gehrie EA, Ness PM. Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions. *Transfusion* 2018;58: 1647-53.
29. Erony SM, Marshall CE, Gehrie EA, Boyd JS, Ness PM, Tobian AAAR, Carroll KC, Blagg L, Shifflett L and **Bloch EM**. The epidemiology of bacterial culture positive transfusion reactions at a large tertiary academic center: 2009-2016. *Transfusion* 2018;58: 1933-9.
30. **Bloch EM**, Ingram C, Hull J, Fawcus S, Anthony J, Green-Thompson R, Crookes RL, Ngcobo S, Creel D, Courtney L, Bellairs GRM, Murphy EL for the South Africa Program of the NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Risk factors for peripartum blood transfusion in South Africa: a case control study. *Transfusion* 58: 2149-2156.
31. Leiby DA, O'Brien SF, Wendel S, Nguyen ML, Delage G, Devare SG, Hardiman A, Nakhasi HL, Saulea S, **Bloch EM**. International survey on the impact of parasitic infections: frequency of transmission and current mitigation strategies. *Vox Sang* 2019;114: 17-27.
32. Kacker S, **Bloch EM**, Ness PM, Gehrie EA, Marshall CE, Lokhandwala PM, Tobian AAR. Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions. *Transfusion* 2019;59: 1291-9.
33. Haddaway K, **Bloch EM**, Tobian AART, Frank SM, Sikorski R, Cho B, Zheng G, Jani J, Lokhandwala P, Lawrence C, Blagg L, Ness PM, Kickler T, Gehrie EA. Hemostatic Properties of Cold Stored Whole Blood Leukoreduced Using Platelet-Sparing vs Non-Platelet-Sparing Filters. *Transfusion* 2019, 59; 1809-1817.
34. Patel EU, White JL, **Bloch EM**, Grabowski MK, Gehrie EA, Lokhandwala PM, Bruner PAR, Goel R, Shaz BH, Ness PM, Tobian AAR. Association of blood donation with iron deficiency among adolescent and adult females in the United States: a nationally representative study. *Transfusion* 2019;59: 1723-33.

35. Gehrie EA, M. Frank SM, Visagie M, Grabowski MK, Tobian AAR, Strockbine VS, DeMario VM, Lawrence C, Hambley B, Uglik K, Ness PM, Dezern A, **Bloch EM**. One-unit Compared To Two-unit Unit Platelet Transfusions for Adult Oncology Outpatients. *Vox Sanguinis* 2019.
36. Ansah D, Weaver J, Munoz B, **Bloch EM**, Coles C, Lietman T, West S. A Cross-Sectional Study of the Availability of Azithromycin in Local Pharmacies and Associated Antibiotic Resistance in Communities in Kilosa District, Tanzania. *Am J Trop Med Hyg* 2019;100: 1105-9.
37. West S, **Bloch EM**, Weaver J, Munoz B, Mrango Z, Kasubi M, Lietman T, Coles C. Morbidity in a longitudinal cohort of children residing in villages randomized to 6 monthly treatment with azithromycin versus placebo. *Clin Infect Dis* 2019.
38. Patel EU, **Bloch EM**, Grabowski MK, Goel R, Lokhandwala PM, Brunker PAR, White JL, Shaz B, Ness PM, Tobian AAR. Sociodemographic and behavioral characteristics associated with blood donation in the United States: a population-based study. *Transfusion* 2019;59: 2899-907.
39. Pascoe EL, Stephenson N, Abigana A, Clifford D, Gabriel M, Wengert G, Brown R, Higley M, **Bloch EM**, Foley JE. Human Seroprevalence of Tick-Borne Anaplasma phagocytophilum, Borrelia burgdorferi, and Rickettsia Species in Northern California. *Vector Borne Zoonotic Dis* 2019;19: 871-8.
40. **Bloch EM**, Mrango Z, Kasubi M, Weaver J, Mihailovic A, Munoz B, Weimer A, Levin A, Tonnetti L, Linnen JM, Bres V, Norris DE, Carpi G, West SK. The Babesia observational antibody (BAOBAB) study: A cross-sectional evaluation of Babesia in two communities in Kilosa district, Tanzania. *PLoS Negl Trop Dis* 2019;13: e0007632.
41. **Bloch EM**, Munoz B, Mrango Z, Weaver J, Mboera LEG, Lietman TM, Sullivan DJ, Jr., West SK. The impact on malaria of biannual treatment with azithromycin in children age less than 5 years: a prospective study. *Malar J* 2019;18: 284.
42. **Bloch EM**, Coles CL, Mabula K, Weaver J, Mrango Z, Munoz B, Lietman TM, West SK. Biannual treatment of preschool children with single dose azithromycin to reduce mortality: impact on azithromycin resistance in the MORDOR trial in Tanzania. *Am J Trop Med Hyg* 2020.
43. **Bloch EM**, Hull J, Green-Thompson R, Ingram C, Crookes RL, Fawcus S, Anthony J, Courtney L, N. Roubinian N, Jauregui A, Hilton JF, Murphy EL for the NHLBI REDS-III South Africa Program. Antenatal blood transfusion in South Africa: indications and practice in a high HIV prevalence setting. *Transfusion* 2020;60: 479-87.
44. Lally K, Kruse RL, Smetana H, Davis R, Roots A, Marshall C, Ness PM, DeZern AE, Gladstone DE, Brennan DC, Desai NM, Tobian AAR, **Bloch EM**, Gehrie EA. Isohemagglutinin titrating performed on an automated solid phase analyzer is comparable to results obtained by manual gel testing. *Transfusion* 2020;60: 628-36.
45. **Bloch EM**, Munoz B, Weaver J, Mrango Z, Lietman TM, West SK. The impact of biannual azithromycin on anemia in preschool children in Kilosa district, Tanzania: a cluster randomized clinical trial. *Am J Trop Med Hyg* 2020.
46. Goel R, Tobian AAR, Makhani S, Patel EU, Frank SM, Ness PM, **Bloch EM**, Gehrie EA, Lokhandwala PM, Nellis MM, Karam O, Patel RM, Josephson CD. Association of Perioperative RBC Transfusions and Venous Thromboembolism in Children and Neonates. *Pediatrics* 2020;145.
47. Murphy KJ, Conroy AL, Ddungu H, Shrestha R, Kyeyune-Byabazaire D, Petersen MR, Musisi E, Patel EU, Kasirye R, **Bloch EM**, Lubega I, John CC, Hume HA, Tobian AAR. Malaria parasitemia among blood donors in Uganda. *Transfusion* 2020;60: 955-64.
48. Kacker S, Katz LM, Ness PM, **Bloch EM**, Goel R, Gehrie EA, Lokhandwala PM, Tobian AAR. Financial Analysis of Large Volume Delayed Sampling to Reduce Bacterial Contamination of Platelets. *Transfusion* 2020;60: 997-1002.
49. **Bloch EM**, Kipiani E, Shadaker S, Alkhazashvili M, Gvinjilia L, Kuchuloria T, Chitadze N, Keating SM, Gamkrelidze A, Turdziladze A, Getia V, Nasrullah M, Averhoff F, Izoria M, Skaggs B. Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program. *Transfusion* 2020;60: 1243-52.
50. Kruse RL, Neally M, Cho BC, **Bloch EM**, Lokhandwala PM, Ness PM, Frank SM, Aaron A.R. Tobian AAR, Gehrie EA. Cryoprecipitate utilization patterns observed with a required prospective approval process versus electronic dosing guidance. *American Journal of Clinical Pathology*. 2020;154(3):362-8.
51. Goel R, Josephson CD, Patel EU, Petersen MR, Packman Z, Gehrie E, **Bloch EM**, Lokhandwala P, Ness PM, Katz L, Nellis M, Karam O, Tobian AAR. Individual- and Hospital-level Correlates of Red Blood Cell, Platelet, and Plasma Transfusions among Hospitalized Children and Neonates: A Nationally Representative Study in the United States. *Transfusion* 2020;60: 1700-12.
52. Fenwick AJ, Gehrie EA, Marshall CE, Tobian AAR, Shrestha R, Kacker S, Brunker PAR, Shifflett L, Carroll KC, Gozelancyzk D, Goel R, Ness PM, **Bloch EM**. Secondary bacterial culture of platelets to mitigate transfusion-associated sepsis: a three-year analysis at a large academic institution. *Transfusion* 2020;60: 2021-8.

53. **Bloch EM**, Goel R, Wendel S, Bumouf T, Al-Riyami AZ, Ang AL, DeAngelis V, Dumont LJ, Land K, Cheuk-Lee C-K, Oreh A, Patidar G, Spitalnik SL, Vermeulen M, Hindawi S, Van den Berg K, Tiberghien P, Vrieling H, Young P, Devine D, So – Osman C on behalf of the ISBT Convalescent Plasma Working Group. Guidance for the Procurement of COVID-19 Convalescent Plasma: Differences between High and Low-Middle Income Countries. *Vox Sang* 2021;116: 18-35.
54. Al-Riyami AZ, Schäfer R, Van den Berg K, **Bloch EM**, Escourt LJ, Goel R, Hindawi S, Josephson CD, Land K, McQuilten ZK, Spitalnik SL, Wood EM, Devine D, So – Osman C on behalf of the ISBT Convalescent Plasma Working Group. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focused gap analysis with recommendations for future research priorities. *Vox Sang* 2021;116: 88-98.
55. Goel R, Petersen MR, Patel EU, Packman Z, **Bloch EM**, Gehrie EA, Lokhandwala PM, Ness PM, Shaz B, Katz LM, Frank SM, Tobian AAR. Comparative Changes of Pre-Operative Autologous Transfusions and Peri-Operative Cell Salvage in the United States. *Transfusion* 2020;60: 2260-71.
56. Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, Littlefield K, Kumar S, Naik HM, Betenbaugh MJ, Shrestha R, Wu AA, Hughes RM, Burgess I, Caturegli P, Laeyendecker O, Quinn TC, Sullivan D, Shoham S, Redd AD, **Bloch EM**[†], Casadevall A[†], Tobian AA[†]. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. *J Clin Invest* 2020;**130**: 6141-50.
57. Benner SE, Patel EU, Laeyendecker O, Pekosz A, Littlefield K, Eby Y, Fernandez RE, Miller J, Kirby CS, Keruly M, Klock E, Baker OR, Schmidt HA, Shrestha R, Burgess I, Bonny TS, Clarke W, Caturegli P, Sullivan D, Shoham S, Quinn TC, **Bloch EM**, Casadevall A, Tobian AAR, Redd AD. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. *J Infect Dis* 2020;**222**: 1974-84.
58. Patel E, **Bloch EM**, Clarke W, Hsieh Y-H, Boon D, Eby Y, Fernandez R, Baker O, Keruly M, Kirby C, Klock E, Littlefield K, Miller J, Schmidt H, Sullivan P, Piwowar-Manning E, Shrestha R, Redd A, Rothman R, Sullivan D, Shoham S, Casadevall A, Quinn T, Pekosz A, Tobian AAR, Laeyendecker O. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. *J Clin Microbiol* 2021;59.
59. Conklin S, Martin K, Manabe Y, Schmidt H, Miller J, Keruly M, Klock E, Kirby C, Baker O, Fernandez R, Eby Y, Hardick J, Shaw-Saliba K, Rothman R, Caturegli P, Redd A, Tobian AAR, **Bloch EM**, Larman H, Quinn T, Clarke W, Laeyendecker O. Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care Testing. *J Clin Microbiol* 2021. Jan 21;59(2):e02020-20.
60. Bonny TS, Patel EU, Zhu X, **Bloch EM**, M. Kate Grabowski MK, Alison G. Abraham AG, Littlefield K, Shrestha R, Sarah E. Benner SE, Laeyendecker O, Shoham S, Sullivan D, Quinn TC, Casadevall A, Pekosz A, Redd AD, Tobian AAR. Cytokine and Chemokine Levels in COVID-19 Convalescent Plasma. *Open Forum Infect Dis* 2021;8: ofaa574
61. Brummitt SI, Kjemtrup AM, Harvey DJ, Petersen JM, Sexton C, Replogle A, Packham AE, **Bloch EM**, Barbour AG, Krause PJ, Green V, Smith WA. *Borrelia burgdorferi* and *Borrelia miyamotoi* Seroprevalence in California Blood Donors. *PLoS One*. 2020;15(12):e0243950.
62. Ahmad Y, Heroes A-S, Hume HA, Farouk M, Owusu-Ofori A, Gehrie EA, Goel R, Ness PM, Tobian AAR, **Bloch EM**. Bacterial contamination of blood products in Africa. *Transfusion* 2021;61: 767-80.
63. Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, **Bloch EM**, Littlefield K, Wieland-Alter W, Connor RI, Wright PF, Benner SE, Bonny TS, Laeyendecker O, Sullivan D, Shoham S, Quinn TC, Larman HB, Casadevall A, Pekosz A, Redd AD, Tobian AAR, Ackerman ME. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. *mBio* 2021;**12**.
64. **Bloch EM**[†], Patel EU[†], Marshall C, Littlefield K, Goel R, Grossman BJ, Winters JL, Shrestha R, Burgess I, Laeyendecker O, Shoham S, Sullivan D, Gehrie EA, Redd AD, Quinn TC, Casadevall A, Pekosz A, Tobian AAR. ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. *Vox Sang* 2021;**116**: 766-73.
65. Kared H[†], Redd AD[†], **Bloch EM**[†], Bonny TS, Sumatoh H, Kairi F, Carbajo D, Abel B, Newell EW, Bettinotti MP, Benner SE, Patel EU, Littlefield K, Laeyendecker O, Shoham S, Sullivan D, Casadevall A, Pekosz A, Nardin A, Fehlings M, Tobian AA, Quinn TC. SARS-CoV-2-specific CD8⁺ T cell responses in convalescent COVID-19 individuals. *J Clin Invest* 2021;131.
66. Thompson EA, Cascino K, Ordonez AA, Zhou W, Vaghshias A, Hamacher-Brady A, Brady NR, Sun IH, Wang R, Rosenberg AZ, Delannoy M, Rothman R, Fenstermacher K, Sauer L, Shaw-Saliba K, **Bloch EM**, Redd AD, Tobian AAR, Horton M, Smith K, Pekosz A, D'Alessio FR, Yegnasubramanian S, Ji H, Cox AL, Powell JD. Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. *Cell Rep* 2021;**34**: 108863.
67. Morgenlander WR, Henson SN, Monaco DR, Chen A, Littlefield K, **Bloch EM**, Fujimura E, Ruczinski I, Crowley AR, Natarajan H, Butler SE, Weiner JA, Li MZ, Bonny TS, Benner SE, Balagopal A, Sullivan D, Shoham

- S, Quinn TC, Eshleman SH, Casadevall A, Redd AD, Laeyendecker O, Ackerman ME, Pekosz A, Elledge SJ, Robinson M, Tobian AA, Larman HB. Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. *J Clin Invest* 2021;**131**.
68. Hull JC, **Bloch EM**, Ingram C, Crookes R, Vaughan J, Courtney L, Jauregui A, Hilton JF, Murphy EL. Slower response to treatment of iron deficiency anaemia in HIV-infected pregnant women: a prospective cohort study. *BJOG* 2021;**128**: 1674-81.
69. Crowder LA, Wendel S, **Bloch EM**, O'Brien SF, Delage G, Sauleda S, Leiby DA for the WP-TTID Subgroup on Parasites. International Survey of Strategies to Mitigate Transfusion-Transmitted *Trypanosoma cruzi* in Non-Endemic Countries, 2016-2018. *Vox Sanguinis* 2021
70. Redd AD, Nardin A, Kared H, **Bloch EM**, Pekosz A, Laeyendecker O, Abel B, Fehlings M, Quinn TC, Tobian AAR. CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants. *Open Forum Infect Dis* 2021;**8**: ofab143.
71. Goel R, Xianming Zhu X, Sarah Makhani S, Molly Petersen M, Josephson CD, Katz LM, Shaz BH, Austin R, Ness PM, Gehrie EA, Frank SM, **Bloch EM**, Tobian AAR. Blood Transfusions in Gunshot Wound Related Emergency Department Visits and Hospitalizations in the United States. *Transfusion* 2021;**61**: 2277-89.
72. Chidambaram V, Jones J, Lokhandwala P, **Bloch EM**, Lanzkron S, Stewart R, Pecker LH. Low Rates of Transfusion Transmitted Infection Screening in Chronically Transfused Adults with Sickle Cell Disease. *Transfusion* 2021;**61**: 2421-9.
73. O'Brien SF, Drews SJ, Yi Q-L, **Bloch EM**, Ogden NH, Koffi JK, Robbin Lindsay, Gregoire Y, Delage G. Risk of transfusion-transmitted babesia microti in Canada, *Transfusion* 2021;**61**: 2958-68.
74. Wake LM, Allison DB, Ware AD, Hooper JE, Baras AS, **Bloch EM**, Clarke W, Burns KH, Sfanos KS, Borowitz MJ, Steenbergen C, Halushka MK, Ralph H. Hruban RH, Marissa J. White MJ. Pathology Residency Program Special Expertise Tracks Meet the Needs of an Evolving Field. *Academic Pathology* 2021.
75. Lam B, Kung YJ, Lin J, Tseng SH, Tsai YC, He L, Castiglione G, Egbert E, Duh EJ, **Bloch EM**, Tobian AAR, Milstone AM, Roden RBS, Wu TC, Hung CF. In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential. *Cell Rep* 2021;**37**: 109838.
76. **Bloch EM**, Mrango Z, Weaver J, Munoz B, Lietman TM, West SK. Causes of death after biannual azithromycin treatment: A community-level randomized clinical trial. *PLoS One* 2021;**16**: e0250197.
77. Kruse RL, Huang Y, Lee A, Zhu X, Shrestha R, Laeyendecker O, Littlefield K, Pekosz A, **Bloch EM**, Tobian AAR, Wang ZZ. A hemagglutination-based, semi-quantitative test for point-of-care determination of SARS-CoV-2 antibody levels. *J Clin Microbiol* 2021;**59**: e01186-21
78. Heaney CD, Pisanic N, Randad PR, Kruczynski K, Howard T, Zhu X, Littlefield K, Patel EU, Shrestha R, Laeyendecker O, Shoham S, Sullivan D, Gebo K, Hanley D, Redd AD, Quinn TC, Casadevall A, Zenilman JM, Pekosz A, **Bloch EM**, Tobian AAR. Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers. *J Clin Virol* 2021;**145**: 104997
79. Goel R, Zhu X, Patel EU, Crowe EP, Ness PM, Katz LM, **Bloch EM**, Tobian AAR. Blood transfusion trends in the United States: national inpatient sample, 2015 to 2018. *Blood Adv* 2021;**5**: 4179-84.
80. Gordon O, Brosnan MK, Yoon S, Jung D, Littlefield K, Ganesan A, Caputo CA, Li M, Morgenlander WR, Henson SN, Ordonez AA, De Jesus P, Tucker EW, Peart Akindele N, Ma Z, Wilson J, Ruiz-Bedoya CA, Younger MEM, **Bloch EM**, Shoham S, Sullivan D, Tobian AA, Cooke KR, Larman B, Gobburu JV, Casadevall A, Pekosz A, Lederman HM, Klein SL, Jain SK. Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. *JCI Insight* 2021.
81. Sait AS, Chiang TP, Marr KA, Massie AB, Cochran W, Shah P, Brennan DC, Thomas AG, Mehta Steinke S, Permpalung N, Shoham S, Merlo C, Jain T, Boyarsky B, Chamaya O, Gurakar A, Sharma K, Durand CM, Werbel WA, Huang CY, Ostrander D, Desai N, Kim MY, Alasfar S, **Bloch EM**, Tobian AAR, Garonzik-Wang J, Segev DL, Avery RK. Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. *Transplant Direct* 2022;**8**: e1268.
82. Senefeld JW[†], Johnson PW[†], Kunze KL[†], **Bloch EM**[†], van Helmond N[†], Golafshar MA, Klassen SA, Klompas AM, Sexton MA, Diaz Soto JC, Grossman BJ, Tobian AAR, Goel R, Wiggins CC, Bruno KA, van Buskirk CM, Stubbs JR, Winters JL, Casadevall A, Paneth NS, Shaz BH, Petersen MM, Sachais BS, Buras MR, Wiczorek MA, Russoniello B, Dumont LJ, Baker SE, Vassallo RR, Shepherd JRA, Young PP, Verdun NC, Marks P, Haley NR, Rea RF, Katz L, Herasevich V, Waxman DA, Whelan ER, Bergman A, Clayburn AJ, Grabowski MK, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Buchholtz ZA, Pletsch MC, Wright K, Greenshields JT, Joyner MJ, Wright RS, Carter RE, Fairweather D. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. *PLoS Med* 2021;**18**: e1003872.

83. **Bloch EM**, Day JR, Krause PJ, Kjemtrup A, O'Brien SF, Tobian AAR, Goel R. Epidemiology of Hospitalized Patients with Babesiosis, United States, 2010-2016. *Emerg Infect Dis* 2022;**28**: 354-62.
84. Barnes LS, Al-Riyami AZ, Ipe TS, **Bloch EM**, Sibinga CS, Eichbaum QG. COVID-19 and the impact on blood availability and transfusion practices in low- and middle-income countries. *Transfusion* 2022;**62**: 336-45.
85. Barnes LS, Stanley J, **Bloch EM**, Pagano MB, Ipe TS, Eichbaum Q, Wendel S, Indrikovs A, Cai W, Delaney M. Status of hospital-based blood transfusion services in low-income and middle-income countries: a cross-sectional international survey. *BMJ Open* 2022;**12**: e055017.
86. Natarajan H, Xu S, Crowley AR, Butler SE, Weiner JA, **Bloch EM**, Littlefield K, Benner SE, Shrestha R, Ajayi O, Wieland-Alter W, Sullivan D, Shoham S, Quinn TC, Casadevall A, Pekosz A, Redd AD, Tobian AAR, Connor RI, Wright PF, Ackerman ME. Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. *BMC Immunol* 2022;**23**: 7.
87. Beck E, Hsieh Y-H, Fernandez R, Dashler G, Egbert E, STruelove S, Garliss C, Wang R, **Bloch E**, Shrestha R, Blankson J, Cox A, Manabe Y, Kickler T, Rothman R, Redd A, Tobian A, Milstone A, TQuinn T, Laeyendecker O. Differentiation of SARS-CoV-2 previously infected and vaccinated individuals in an inner-city emergency department. *Journal of Clinical Microbiology* 2022.
88. Kruse RL, Albayda J, Vozniak SO, Lawrence SE, Goel R, Lokhandwala PM, Ness PM, Tobian AAR, **Bloch EM**, Crowe EP. Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy. *Journal of Clinical Apheresis* 2022.
89. Al-Riyami AZ, Burnouf T, Wood EM, Devine DV, Oreh A, Apelseth TO, Goel R, **Bloch EM**, van Den Berg K, Getshen M, Louw V, Ang AL, Lee CK, Rahimi-Levene N, Stramer SL, Vassallo R, Schulze TJ, Patidar GK, Pandey HC, Dubey R, Badawi M, Hindawi S, Meshi A, Matsushita T, Sorrentino E, Grubovic Rastvorceva RM, Bazin R, Vermeulen M, Nahirniak S, Tsang HC, Vrieling H, Triyono T, Addas-Carvalho M, Hećimović A, Torres OW, Mutindu SM, Bengtsson J, Dominguez D, Sayedahmed A, Hanisa Musa R, Gautam B, Herczenik E, So-Osman C. International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic. *Vox Sang* 2022.
90. Park HS, Shapiro JR, Sitaras I, Woldemeskel BA, Garliss CC, Dziedzic A, Sachithanandham J, Jedlicka AE, Caputo CA, Rousseau KE, Thakar M, Suwanmanee S, Hauk P, Aliyu L, Majewska NI, Koley S, Patel B, Broderick P, Mosnaim G, Heath SL, Spivak ES, Shenoy A, **Bloch EM**, Gniadek TJ, Shoham S, Casadevall A, Hanley D, Cox AL, Laeyendecker O, Betenbaugh MJ, Cramer SM, Mostafa HH, Pekosz A, Blankson JN, Klein SL, Tobian AA, Sullivan D, Gebo KA. Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. *JCI Insight* 2022;**7**.
91. Crowley AR, Natarajan H, Hederman AP, Bobak CA, Weiner JA, Wieland-Alter W, Lee J, **Bloch EM**, Tobian AAR, Redd AD, Blankson JN, Wolf D, Goetghebuer T, Marchant A, Connor RI, Wright PF, Ackerman ME. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike. *Elife* 2022;**11**.
92. Sullivan DJ, Gebo KA, Shoham S, **Bloch EM**, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF. Early Outpatient COVID-19 Treatment Trial with Convalescent Plasma. *N Engl J Med* 2022;**386**: 1700-11.
93. Li M, Beck EJ, Laeyendecker O, Eby Y, Tobian AAR, Caturegli P, Wouters C, Chiklis GR, Block W, McKie RO, Joyner MJ, Wiltshire TD, Dietz AB, Gniadek TJ, Shapiro AJ, Yarava A, Lane K, Hanley DF, **Bloch EM**, Shoham S, Cachay ER, Meisenberg BR, Huaman MA, Fukuta Y, Patel B, Heath SL, Levine AC, Paxton JH, Anjan S, Gerber JM, Gebo KA, Casadevall A, Pekosz A, Sullivan DJ. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. *Blood Adv* 2022;**6**: 3678-83.
94. Redd AD, Nardin A, Kared H, **Bloch EM**, Abel B, Pekosz A, Laeyendecker O, Fehlings M, Quinn TC, Tobian AAR, Goff SP. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8+ T-Cell Epitopes Identified in COVID-19 Convalescent Individuals. *mBio* 2022;**13**: e03617-21.
95. Day JR, Takemoto C, Sharathkumar A, Makhani S, Gupta A, Bitner S, Josephson CD, **Bloch EM**, Tobian AAR, Krishnamurti L, Goel R. Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates. *Haemophilia* 2022.
96. Shoham S, **Bloch EM**, Casadevall A, Hanley D, Lau B, Gebo K, Cachay E, Kassaye SG, Paxton JH, Gerber J, Levine AC, Naeim A, Currier J, Patel B, Allen ES, Anjan S, Appel L, Baksh S, Blair PW, Bowen A, Broderick P, Caputo CA, Cluzet V, Cordisco ME, Cruser D, Ehrhardt S, Forthal D, Fukuta Y, Gawad AL, Gniadek T, Hammel J, Huaman MA, Jabs DA, Jedlicka A, Karlen N, Klein S, Laeyendecker O, Lane K, McBee N,

- Meisenberg B, Merlo C, Mosnaim G, Park HS, Pekosz A, Petrini J, Rausch W, Shade DM, Shapiro JR, Singleton JR, Sutcliffe C, Thomas DL, Yarava A, Zand M, Zenilman JM, Tobian AAR, Sullivan DJ. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. *Clin Infect Dis* 2023;**76**: e477-e86.
97. Saraf S, Zhu X, Shrestha R, Bonny TS, Baker OR, Beck EJ, Fernandez RE, Eby Y, Akinde O, Ruff JE, Caturegli P, Redd AD, **Bloch EM**, Quinn TC, Tobian AAR, Laeyendecker O. Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals. *PLoS One* 2022;**17**: e0264298.
98. Jones JM, Swett AD, Crowe E, Lawrence C, **Bloch EM**, Lanzkron SM. Implementation of national blood conservation recommendations at an adult sickle cell center. *Transfusion* 2022.
99. Credle JJ, Gunn J, Sangkhapreecha P, Monaco DR, Zheng XA, Tsai HJ, Wilbon A, Morgenlander WR, Rastegar A, Dong Y, Jayaraman S, Tosi L, Parekkadan B, Baer AN, Roederer M, **Bloch EM**, Tobian AAR, Zyskind I, Silverberg JJ, Rosenberg AZ, Cox AL, Lloyd T, Mammen AL, Benjamin Larman H. Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries. *Nat Biomed Eng* 2022;**6**: 992-1003.
100. Makhani SS, Schwartz J, Vasovic LV, DeSimone RA, Kaicker S, Bussel J, Crowe EP, **Bloch EM**, Tobian AAR, Goel R. Therapeutic plasma exchange practices in immune thrombocytopenia related hospitalizations: Results from a nationally representative sample. *J Clin Apher* 2022.
101. **Buban KR**, Lawrence CE, Zhu XJ, Tobian AAR, Gehrie EA, Vozniak S, Shrestha R, Lokhandwala PM, **Bloch EM**. Algorithm-based selection of automated red blood cell exchange procedure goals reduces blood utilization in chronically transfused adults with sickle cell disease. *J Clin Apher* 2022;**37**: 468-75.
102. Al-Riyami AZ, Estcourt L, Rahimi-Levene N, **Bloch EM**, Goel R, Tiberghien P, Thibert JB, Bruun MT, Devine DV, Gammon RR, Wendel S, Toungouz Nevessignsky M, Grubovic Rastvorceva RM, Oreh A, Romon I, van den Berg K, Kitazawa J, Patidar G, So-Osman C, Wood EM. Early and out-of-hospital use of COVID-19 convalescent plasma: An international assessment of utilization and feasibility. *Vox Sang* 2022;**117**: 1202-10.
103. Kostandova N, Drabo EF, Yenokyan K, Wesolowski A, Truelove S, **Bloch EM**, Tobian AAR, Vassallo RR, Bravo MD, Casadevall A, Lessler J, Lau B. Comparison of allocation strategies of convalescent plasma to reduce excess infections and mortality from SARS-CoV-2 in a US-like population. *Transfusion* 2022.
104. Kandathil AJ, Benner SE, **Bloch EM**, Shrestha R, Ajayi O, Zhu X, Caturegli PP, Shoham S, Sullivan D, Gebo K, Quinn TC, Casadevall A, Hanley D, Pekosz A, Redd AD, Balagopal A, Tobian AAR. Absence of pathogenic viruses in COVID-19 convalescent plasma. *Transfusion* 2022.
105. Spencer BR, White JL, Patel EU, Goel R, **Bloch EM**, Tobian AA. Eligibility Considerations for Female Whole Blood Donors: Hemoglobin Levels and Iron Status in a Nationally Representative Population. *Transfus Med Rev* 2022.
106. **Bloch EM**, Zhu X, Krause PJ, Patel EU, Grabowski MK, Goel R, Auwaerter PG, Tobian AAR. Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States. *Open Forum Infect Dis* 2022;**9**: ofac597.
107. Sparks R, Lau WW, Liu C, Han KL, Vrindten KL, Sun G, Cox M, Andrews SF, Bansal N, Failla LE, Manischewitz J, Grubbs G, King LR, Koroleva G, Leimenstoll S, Snow L, Chen J, Tang J, Mukherjee A, Sellers BA, Apps R, McDermott AB, Martins AJ, **Bloch EM**, Golding H, Khurana S, Tsang JS. Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19. *Nature* 2023.
108. **Bloch EM**†, Siller A†, Tonnetti L, Drews SJ, Spencer BR, Hedges D, Mergenthal T, Weber-Schehl M, Astl M, Patel EU, Gaber M, Schennach H for the ISBT TTID Working Party Parasite subgroup. Molecular screening of blood donors for Babesia in Tyrol, Austria. *Transfusion Medicine and Hemotherapy* 2023.

In press

109. Ipe TS, Eichbaum Q, El-Ekiabi M, Owusu-Ofori S, Vermeulen M, Mapako T, Tayou C, Dembele B, **Bloch EM**†, Barnes LS† for the AABB Global Transfusion Forum. Transfusion Medicine Research in Africa: insights from investigators in the field. *Vox Sanguinis* 2023.
110. Gammon RR, Hindawi S, Al-Riyami AZ, Ang AL, Bazin R, **Bloch EM**, Counts K, de Angelis V, Goel R, Rastvorceva RMG, Ilaria P, Lee C-K, La raja M, Mengoli C, Oreh A, Patidar GK, Rahimi-Levene N, Ravula U, Rexer K, So-Osman C, Thachil J, Nevessignsky MT, Vermeulen M. The Use of Predictive Modelling to Determine the Likelihood of Donor Return During the COVID-19 Pandemic. *Transfusion Medicine* 2023.
111. Baksh S, Heath S, Fukuta Y, Shade D, Meisenberg B, **Bloch EM**, Tobian AAR, Spivak E, Patel B, Gerber J, Jay Raval, Forthal D, Paxton J, Mosnaim G, Yarva A, Casadevall A, Sullivan D, Hanley D, Gebo KA, on behalf of

the CSSC-004 Consortium. Symptom duration and resolution with early outpatient treatment of Convalescent Plasma for COVID-19: a randomized trial. *Journal of Infectious Diseases* 2023

† co- first or co-senior author

Review Articles [RA]

1. **Bloch EM**, Vermeulen M, Murphy E. Blood Transfusion Safety in Africa: A literature review of infectious disease and organizational challenges. *Transfus Med Rev* 2012;26: 164-80.
2. Van den Berg K, Van Hasselt J, **Bloch E**, Crookes R, Kelley J, Berger J, Ingram C, Dippenaar A, Thejpal R, Littleton N, Elliz T, Reubenson G, Cotton M, Hull JC, Moodley P, Goga Y, Eldridge W, Patel M, Hefer E, Bird A. A review of the use of blood and blood products in HIV-infected patients. *S Afr J HIV Med* 2012;13(2):87-103
3. **Bloch EM**, Jackman RP, Lee TH, Busch MP. Transfusion-associated microchimerism: the hybrid within. *Transfus Med Rev* 2013;27: 10-20.
4. Pruett CR, Vermeulen M, Zacharias P, Ingram C, Tagny CT, **Bloch EM**. The use of rapid diagnostic tests for transfusion infectious screening in Africa: a literature review. *Transfus Med Rev* 2015;29: 35-44.
5. Plourde A and **Bloch EM**. *A Literature Review of Zika Virus*. *Emerg Infect Dis* 2016; 22(7).
6. Morar MM, Pitman J, McFarland W, **Bloch EM**. The Contribution of Unsafe Blood Transfusion to HIV Incidence in sub-Saharan Africa: Re-examination of the 5% to 10% Convention. *Transfusion* 2016 Dec;56(12):3121-32
7. Jimenez A, Shaz BH, **Bloch EM**. *Zika Virus and the Blood Supply: What do we know?* *Transfus Med Rev*. 2017; 31(1): 1-10.
8. Gehrie EA, Ness PM, **Bloch EM**, Kacker S, Tobian AAR. Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease. *Transfusion* 2017;57: 2267-76.
9. Gordy AD, Cyril Jacquot C, Tobian AAR, Gehrie E, Ness PM, **Bloch EM**. *Pathogen Reduction and Blood Transfusion Safety in Africa: Strengths, Limitations, and Challenges of Implementation in Low Resource Settings*. *Vox Sang* 2018;113: 3-12.
10. Weimer A, Tagny CT, Tapko JB, Gouws C, Tobian AAR, Ness PM, **Bloch EM**, 2019. Blood transfusion safety in sub-Saharan Africa: A literature review of changes and challenges in the 21st century. *Transfusion* 59: 412-427.
11. Ifland L, **Bloch EM**, Pitman JP. Funding blood safety in the 21st century. *Transfusion* 2018;58: 105-12.
12. Busch MP, **Bloch EM**, Kleinman S. Prevention of Transfusion Transmitted Infections. *Blood* 2019; 133: 1854-64.
13. **Bloch EM**, Kumar S, Krause PJ. Persistence of Babesia microti Infection in Humans. *Pathogens* 2019;8.
14. **Bloch EM**. A risk-based decision-making framework for blood safety: what's the case for Zika? *ISBT Science Series* 2019;0.
15. **Bloch EM**, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ, Paneth N, Gehrie E, Spitalnik S, Hod EA, Pollack L, Nicholson WT, Pirofski LA, Bailey JA, Tobian AA. Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest* 2020;130: 2757-65.
16. Ryan N, Vieira D, Goffman D, **Bloch EM**, Akaba GO, D'mello BS, Egekeze C, Snyder A, Lyimo M, Nnodu O, Peprah E. Implementation outcomes of policy and programme innovations to prevent obstetric haemorrhage in low- and middle-income countries: a systematic review. *Health Policy Plan* 2020;35:1208-27.
17. Drews SJ, Spencer BR, Wendel S, **Bloch EM** for the International Society of Blood Transfusion TTID Working Party Parasite Subgroup. Filariasis and transfusion associated risk: a literature review. *Vox Sang* 2021.
18. Goel R†, **Bloch EM**†, Pirenne F, Al-Riyami AZ, Crowe E, Dau L, Land K, Townsend M, Jecko T, Rahimi-Levene N, Patidar G, Josephson CD, Arora S, Vermeulen M, Vrieling H, Montemayor C, Oreh A, Hindawi S, van den Berg K, Serrano K, So-Osman C, Wood E, Devine DV, Spitalnik SL. ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group. *Vox Sang* 2021;116: 849-61.
19. **Bloch EM**, Krause PJ, Tonnetti L. Preventing Transfusion-Transmitted Babesiosis. *Pathogens* 2021;10.
20. Wendel S, Land K, Devine DV, Daly J, Bazin R, Tiberghien P, Lee CK, Arora S, Patidar GK, Khillan K, Smid WM, Vrieling H, Oreh A, Al-Riyami AZ, Hindawi S, Vermeulen M, Louw V, Burnouf T, **Bloch EM**, Goel R, Townsend M, So-Osman C. Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. *Vox Sang* 2021;116: 872-9.
21. Sarker T, Katz LM, **Bloch EM**, Goel R. Blood Product (Donor) Noninfectious and Infectious Testing and Modification. *Clinics in Laboratory Medicine* 2021;41: 579-98.
22. **Bloch EM**, Tobian AAR, Katz LM. Powassan virus: What is the risk to the blood supply? *Transfusion* 2021;61: 3286-8.

23. **Bloch EM.** Transfusion-transmitted infections. *Annals of Blood* 2021. <https://aob.amegroups.com/article/view/6747/7260>
24. Burnouf T, Gathof B, **Bloch EM**, Bazin R, de Angelis V, Patidar GK, Rastvorceva RMG, Oreh A, Goel R, Rahimi-Levene N, Hindawi S, Al-Riyami AZ, So-Osman C. Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. *Transfus Med Rev* 2022.
25. **Bloch EM**, Sullivan DJ, Shoham S, Tobian AAR, Casadevall A, Gebo KA. The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox. *mBio* 2022;**13**: e0286222.
26. Drews SJ, Wendel S, Leiby DA, Tonnetti L, Ushiro-Lumb I, O'Brien SF, Lieshout-Krikke RW, **Bloch EM.** Climate change and parasitic risk to the blood supply. *Transfusion* 2022.

† co- first or co-senior author

Case Reports [CR]

1. Bagga S, **Bloch EM:** Imaging of a case of invasive malignant thymoma on PET scan with CT and histopathological correlation. *Clin Nuclear Med.* 2006 Oct;**31**(10):614-6
2. **Bloch EM**, Herwaldt BL, Leiby DA, Shaieb A, Herron RM, Chervenak M, Reed W, Hunter R, Ryals R, Hagar W, Xayavong MV, Slemenda SB, Pieniazek NJ, Wilkins PP, Kjemtrup AM. The Third Described Case of Transfusion-Transmitted *Babesia duncani*. *Transfusion* 2011;**52**: 1517-22
3. Rabe, IB, Schwartz, BS, Farnon EC, Josephson SA, Webber AB, Roberts JP, de Mattos AM, Gallay BJ, van Slyck S, Messenger, SL, Yen CJ, **Bloch EM**, Drew CP, Fischer M, Glaser CA for the WNV Transplant Investigation Team. Fatal Transplant-Associated West Nile Virus Encephalitis and Public Health Investigation-California, 2010. *Transplantation* 2013;**96**: 463-8.
4. Gniadek TJ, McGonigle AM, Shirey RS, Brunker PA, Streiff M, Philosophe B, **Bloch EM**, Ness PM, King KE. A Rare, Potentially Life-Threatening Presentation of Passenger Lymphocyte Syndrome. *Transfusion* 2017 May;**57**(5):1262-1266.
5. Lokhandwala PM, Shabihkhani MM, Ness PM, **Bloch EM.** Therapeutic Plasmapheresis for Hyperviscosity Syndrome Secondary to High Rheumatoid Factor. *Transfusion and Apheresis Science.* *Transfus Apher Sci* 2018;**57**: 225-7.
6. Mirihagalle N, Parajulia P, Sundareshanb V, Sahac D, Shahc A, Chuab F, Waqarb S, Prakashb V, Tobian AAR, **Bloch EM**, Katz L, Goel R. Sequential Dosing of Convalescent COVID-19 Plasma with Significant Temporal Clinical Improvements in a Persistently SARS-COV-2 Positive Patient. *Transfusion and Apheresis Science* 2021
7. Nguyen MC, Lee EJ, Avery R, Dioverti-Prono V, Shoham S, Tobian AAR, **Bloch EM**, Gurakar A, Rizkalla NA, Cameron A, King EA, Ottmann S, Garonzik-Wang JM, Wesson RN, Philosophe B. Transplant of SARS-CoV-2-Infected Living Donor Liver: Case Report. *Transplant Direct.* 2021 Aug;**7**(8):e721.
8. Mercure-Corriveau N, O'Brien C, Garg A, Crowe EP, **Bloch EM**, Tobian AAR. Therapeutic plasma exchange for the treatment of extracorporeal membrane oxygenation dysfunction caused by hypertriglyceridemia. *Transfusion* 2022.
9. Costa V, Mercure-Corriveau N, Gourneau J, Tobian AAR, Jones JM, Lauriello A, SLanzkron S, Crowe EP, **Bloch-EM.** Transfusion-transmitted babesiosis in a patient with sickle cell disease undergoing chronic red cell exchange. *Transfusion* 2022.

Book Chapters, Monographs [BC]

1. **Bloch EM.** TM 12-3: Transfusion Transmitted Babesiosis: clinical diagnosis, donor management and screening. *ASCP Check Sample.* ISSN 1056-5949. 2012 Apr;**55**(3) 27-40
2. Genrich G, **Bloch EM.** Transfusion-Transmitted Malaria: Investigation, Donor Screening and Deferral Policy. *ASCP Check Sample.* ISSN 2167 -2180. April 2013 Apr; 56 (3).
3. *Utilization Management in the Clinical Laboratory and Other Ancillary Services.* Chapter Patient Blood Management. Jacquot C, **Bloch EM.** Editors: Lewandrowski, Kent, Sluss, Patrick M. (Eds.) 2017
4. Hsu YS, **Bloch EM.** Approach to hemolysis in the recently transfused patient. *ASCP Case Report (CSTM1605)* 2016.
5. **Bloch EM**, Jacquot C, Shaz B. Chapter *Infectious Complications of Blood Transfusion* in *Transfusion Medicine, Apheresis, and Hemostasis* 1st Ed. Williams HPL III. Review Questions and Case Studies

6. Jimenez A, **Bloch EM**. *Overview of Infectious Disease Testing* in Transfusion Medicine and Hemostasis - 3rd edition Ed. Shaz BH, Hillyer CD and Gil MR. 2018.
7. **Bloch EM**. Coronavirus disease 2019 (COVID-19): Convalescent plasma and hyperimmune globulin. UpToDate 2020.
8. Smith R, **Bloch EM**, Kumar S, Krause PJ. Human Babesiosis. *Molecular Medical Microbiology*-3rd edition. Editors: Tang Y-W et al. In press 2020.
9. **Bloch EM**, Benjamin RJ, Ramirez- Arcos S. Rossi's Principles of Transfusion Medicine, sixth edition: Bacterial contamination of blood products. 2022 Editors: Simon TL, Gehrie EA, McCullough J, Roback JD, Edward L. Snyder EL.

Books, Textbooks [BK]

Global Perspectives and Practices in Transfusion Medicine. 1st Edition. 2022 Editors: Eichbaum Q, Abdella Y, Amar S, Barnes L, **Bloch E**, Delaney M, Ipe T, Smit Sibinga CT, Zacharias PJK (In press).

Editorials [ED]

1. **Bloch EM**. Residual Risk of Bacterial contamination: What are the options? *Transfusion* 2017; 57: 2289-92.
2. **Bloch EM**, Ness PM, Tobian AAR, Sugarman J. Revisiting Blood Safety Practices Given Emerging Data about Zika Virus. *N Engl J Med* 2018;378: 1837-41.
3. Reed W, **Bloch EM**. Capturing the passenger leukocyte. *Transfusion* 2019; **59**(11): 3291-2
4. **Bloch EM**, Krause PJ. Blood Screening for Babesia in the blood supply. *Annals of Blood* 2020.
5. **Bloch EM**. Convalescent plasma to treat COVID-19. *Blood* 2020;136: 654-5.
6. **Bloch EM**, Crowe EP, Tobian AAR. Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer. *J Infect Dis* 2021;223: 740-2.
7. Patel EU, **Bloch EM**, Tobian AAR. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serosurveillance in Blood Donor Populations. *J Infect Dis* 2021.
8. **Bloch EM**. Deferral of men who have sex with men from blood donation: policy and change. *Transfus Clin Biol* 2022; 29:195-197

Guidelines/Protocols, Consensus Statement, Expert Opinion, Consortium Articles [GL]

1. Brown B and Sugarman J and the the HPTN Ethics Working Group. HPTN (HIV Prevention and Treatment Network) Ethics Guidance for Research. Revised February 2020.
2. Cohn CS, Estcourt L, Grossman BJ, Pagano MB, Allen ES, **Bloch EM**, Casadevall A, Devine DV, Dunbar NM, Foroutan F, Gniadek TJ, Goel R, Gorlin J, Joyner MJ, Metcalf RA, Raval JS, Rice TW, Shaz BH, Vassallo RR, Winters JL, Beaudoin G, Tobian AAR. COVID-19 convalescent plasma: Interim recommendations from the AABB. *Transfusion* 2021;**61**: 1313-23.
3. Kasirye R, Hume HA, **Bloch EM**, Lubega I, Kyeyune D, Shrestha R, Ddungu H, Wambongo Musana H, Dhabangi A, Mstat OJ, Bstat PE, de Lange T, Tartakovsky M, White JL, Kakura C, Fowler MG, Musoke P, Nolan M, Grabowski MK, Moulton LH, Susan L. Stramer SL, Whitby D, Zimmerman PA, Wabwire, D, Kajja I, McCullough J, Raymond Goodrich R, Quinn TC, Robert Cortes R, Ness PM, Aaron A.R. Tobian AAR. The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial. *Trials*. 2022; 23: 257.
4. Estcourt LJ, Cohn CS, Pagano MB, Iannizzi C, Kreuzberger N, Skoetz N, Allen ES, **Bloch EM**, Beaudoin G, Casadevall A, Devine DV, Foroutan F, Gniadek TJ, Goel R, Gorlin J, Grossman BJ, Joyner MJ, Metcalf RA, Raval JS, Rice TW, Shaz BH, Vassallo RR, Winters JL, Tobian AAR. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. *Ann Intern Med* 2022;**175**: 1310-21.
5. **Bloch EM**, Focosi D, Shoham S, Senefeld J, Tobian AAR, Baden LR, Tiberghien P, Sullivan D, Cohn C, Dioverti V, Henderson JP, So-Osman C, Juskewitch JE, Razonable RR, Franchini M, Goel R, Grossman BJ, Casadevall A, Joyner MJ, Avery RK, Pirofski L, Gebo K. Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19. *Clinical Infectious Diseases* 2023

Letters, Correspondence [LT]

1. Merin NM, LeVee AA, Merlo CA, Spector K, Coleman H, Klapper E, Hayes C, Zabner R, McDyer JF, Eby YJ, Tobian AAR, **Bloch EM**, Hager DN. The feasibility of multiple units of convalescent plasma in mechanically ventilated patients with COVID-19: A pilot study. *Transfus Apher Sci* 2022.
2. Focosi D, Senefeld JW, Joyner MJ, Sullivan D, Casadevall A, **Bloch EM**, Franchini M. Lower anti-spike levels in B-cell-depleted patients after convalescent plasma transfusion suggest the need for repeated doses. *Br J Haematol* 2022.

Methods and Techniques, “How I Do It” articles [MT]

1. Jimenez A, Shaz BH, Kessler D, **Bloch EM**. How do we manage blood donors and recipients following a positive Zika screening result? *Transfusion* 2017;57: 2077-83.
2. **Bloch EM**, Tobian AAR, Shoham S, Hanley DF, Gniadek TJ, Cachay ER, Meisenberg BR, Kafka K, Marshall C, Heath SL, Shenoy A, Paxton JH, Levine A, Forthal D, Fukuta Y, Huaman MA, Ziman A, Adamski J, Gerber J, Crusier D, Kassaye SG, Mosnaim GS, Patel B, Metcalf RA, Anjan S, Reisler RB, Yarava A, Lane K, McBee N, Gawad A, Raval JS, Zand M, Abinante M, Broderick PB, Casadevall A, DS, Gebo KA. How do I implement an outpatient program for the administration of convalescent plasma for COVID-19? *Transfusion* 2022.
3. Budhai A, Wu AA, Hall L, Strauss D, Paradiso S, Alberigo J, Hillyer CD, Jett B, Tobian AAR, **Bloch EM**, Sachais BS, Shaz BH. How did we rapidly implement a convalescent plasma program? *Transfusion* 2020;60: 1348-55.

Opinions, Perspectives, Political Commentary, Advocacy, Essays [OP]

1. **Bloch EM**, Simon, MS, Shaz, BH. *Emerging Infections and Blood Safety in the 21st Century*. *Ann Intern Med*. 2016 Mar 15;
2. **Bloch EM**, Mast AE, Josephson CD, Klein HG, Eder AF. Teenage Blood Donors: Are We Asking Too Little and Taking Too Much? *Pediatrics* 2017;139.
3. **Bloch EM**, Gehrie EA, Ness PM, Sugarman J, Tobian A. Blood Transfusion Safety in Low-Resourced Countries: Aspiring to a Higher Standard. *Ann Intern Med* 2020;173: 482-3.
4. **Bloch EM**, Goel R, Montemayor C, Cohn C, Tobian AAR. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries. *Transfus Apher Sci* 2020: 102957.
5. Hartmann J, **Bloch EM**, Burnouf T. Experience with COVID-19 convalescent plasma provides vital guidance to future pandemics. *Transfusion* 2022;62: 681-4.

Original Research, other [RO]

None

Proceedings Reports [PR]

1. Zhang JY, Shang T, Ahn D, et al. How to Best Protect People With Diabetes From the Impact of SARS-CoV-2: Report of the International COVID-19 and Diabetes Summit. *J Diabetes Sci Technol*. 2021:1932296820978399.

Certification

2008 Anatomic and Clinical Pathology, Transfusion Medicine

Medical, other state/government licensure

2002- present Health Professions Council of South Africa, Medical and Dental Professions Board, MP0525596, Medical Practitioner

2007-present Medical Board of California, A101679

2015-present Maryland Medical Board, D0080168

Boards, other specialty certification

2008 Anatomic and Clinical Pathology

2009 Transfusion Medicine

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

Date Role, Committees, any explanatory notes

2011-2015 Global Health Sciences Applications Committee Masters program (Global Health)

2013-2015	Member, UCSF, Medical School admissions committee
2014-2015	UCSF-Global Health Sciences-Global Health Pathways to Discovery (Assistant director)
2014-2015	UCSF-Global Health Sciences Education Committee
2014-2015	UCSF RAPTr Review Committee
2015-present	Member, Johns Hopkins University, Medical School admissions committee
2016-present	JHU Residency Admissions Committee (Pathology)
2016-present	JHU Clinical Competency Committee (Transfusion Medicine Post-graduate fellowship)
2018-present	Director, JHU Transfusion Medicine, Post-graduate fellowship
2019-present	Education Advisory Committee, residency program, pathology
2019-present	US FDA, Blood Products Advisory Committee
2020-present	Medical director, JHH Hemapheresis and Transfusion support service
2021-present	Johns Hopkins Medicine Research Council
2022-present	Johns Hopkins School of Medicine Clinical Research Faculty Advisory Group

Editorial Activities

Editorial Board appointments

2018-present	Editorial board member, <i>Transfusion</i>
2018-present	Review Editor, <i>Africa Sanguine</i>
2018-present	Editorial board member, <i>Annals of Blood</i>
2021-present	Editorial board member, <i>Acta Parasitologica</i>
2021-present	Associate Editor, <i>Transfusion Clinique et Biologique</i>
2022-present	Associate Editor, <i>Journal of Clinical Apheresis</i>

Journal peer review activities

2009-present	Transfusion
2010	Transfusion Medicine Reviews
2011	Critical Reviews in Hematology Oncology
2012	Journal of Neonatal-Perinatal Medicine
2012	Virology Journal
2014	Antimicrobial Agents and Chemotherapy
2014	WHO South-East Asia Journal of Public Health
2014	Hepatology
2014-present	International Journal of Clinical Transfusion Medicine
2015-present	Biomed Central (BMC)
2015	Cancer Management and Research
2015	Journal of Neonatology & Clinical Pediatrics
2015	Chimerism
2015	Journal of Virological Methods
2015	Clinical Medicine Insights: Blood Disorders.
2016	Journal of Clinical Apheresis
2016-present	Emerging Infectious Diseases
2016-present	ISBT Science Series
2016	BMJ Global Health
2016	Journal of Infection and Public Health
2016	Journal of Blood Transfusion
2016-present	American Journal of Tropical Medicine & Hygiene
2017	Journal of Parasitology
2018	Epidemiology and Infection
2018	BMC Hematology
2018-present	Blood
2018-present	Vox Sanguinis
2019	Africa Sanguine
2019	Tropical Medicine and Infectious Disease
2020-present	Acta Parasitologica
2020	Applied Health Economics and Health Policy Economic
2020	American Journal of Respiratory and Critical Care Medicine

2020	The Lancet Infectious Diseases
2020	Eurosurveillance
2020	Expert Opinion On Biological Therapy
2020	Lancet Hematology
2020-present	Journal of Clinical Investigation
2021	Revista da Sociedade Brasileira de Medicina Tropical
2021	Clinical Infectious Diseases
2021	Annals of Internal Medicine
2022	Journal of Medical Entomology
2022	Reviews in Medical Virology
2022	PLOS Neglected Tropical Diseases
2022	Nature Communications
2022	Journal of Taibah University Medical Sciences

Other peer review activities

2016	Invited reviewer, Swiss National Science Foundation
2018	Invited reviewer, Scientific Review meeting (abstract selection) ahead of 35 th Congress of ISBT
2019	Invited reviewer, Canadian Blood Services Intramural Research Grant program
2019	Invited reviewer, University of Sharjah
2020	Invited grant reviewer, South African Medical Research Council
2020	Invited reviewer, abstract selection, ahead of Annual AABB meeting
2020	Invited reviewer, Swiss National Science Foundation
2021	Invited reviewer, National Blood Foundation

Advisory Committees, Review Groups/Study Sections

2016-2021	Member, HIV Prevention and Treatment Network Ethics Working Group
2017	Scientific Reviewer, Congressionally Directed Medical Research Programs (CDMRP) Tick borne Diseases Panel
2018-present	Member, Technical Advisory Group, Georgian National Hepatitis C elimination program (Georgian national CDC with technical assistance from US CDC)
2020-present	Invited member, Data Safety Monitoring Board, “Assessment of safety and efficacy of COVID-19 Convalescent Plasma for treatment of COVID-19 in adults in Uganda; A Phase III randomized controlled trial”
2020-present	California Institute for Regenerative Medicine, advisor convalescent plasma program
2021-2022	Co-Chair, NHLBI working group on “Emerging infections: Impact on blood science, the supply, safety, and public health (e.g., SARS-CoV-2 including use of CCP, Arboviruses, Agents of concern) for State of the Science, assigning research priorities in Transfusion Medicine.
2022-	Invited member, AABB Annual Meeting Scientific Program Task Force

Professional Societies

2010	American Society of Clinical Pathologists (ASCP), Wrote questions for Pathologist Recertification individualized Self-Assessment Examination (PRISE)
2010	Wrote questions for Residency and Fellowship In-service Examination (RISE)
2013-present	AABB, assessor
2015-present	International Society of Blood Transfusion (ISBT)-Transfusion Transmitted Infectious Disease Working Group (TTID)
2015-present	ISBT-TTID Working Party- Parasite subgroup (Co-Chair)
2015-2016	AABB, Molecular subcommittee (junior committee member)
2016-2019	AABB, Molecular subcommittee (full committee member)
2016-present	African Society of Blood Transfusion Education committee member
2017-present	AABB, Global Blood Safety Forum, Steering Committee and Policy subcommittee (co-chair research group)
2018-2019	AABB, Education subcommittee
2019-present	AABB, Transfusion transmitted infections subcommittee
2021-present	AABB, Selection of abstracts committee

RECOGNITION

Awards, Honors

Date	Title, description, sponsor, any explanatory notes
1995-1999	<u>Amelia Schenkman scholarship</u> , merit based partial academic scholarship while at University of Cape Town, medical school, ZA
2007-2008	<u>Chief resident</u> , Pathology, Tufts Medical Center, Boston, MA
2008	<u>Donald West King Fellowship in Environmental and Infectious Disease</u> ; Armed Forces Institute of Pathology, DC
2014	<u>Karen Williams Memorial Lecturer</u> , South Central Association of Blood Banks
2018	<u>Clinician Scientist Award</u> , Johns Hopkins University School of Medicine
2021	<u>Young Physician-Scientist Award (YPSA)</u> , ASCI - The American Society for Clinical Investigation

Invited Talks

JHMI/Regional

2008	California Blood Bank Society (Duarte, CA); <i>Emerging Technologies in Transfusion Medicine: Molecular Genotyping of Donors and Patients</i>
2009	California Blood Bank Society (annual meeting, Lake Tahoe, CA); <i>Transfusion transmitted Toxoplasmosis "Letting the Cat out of the Bag" and Babesiosis, "malaria in New England"</i>
2009	Galileo Health Academy; <i>The history of Blood Transfusion and diversity in the blood supply</i>
2009	UCSF Blood Transfusion Service; <i>Emerging Technologies in Transfusion Medicine: Molecular Genotyping of Donors and Patients</i>
2009	Kaiser Permanente Department of Medicine; <i>Transfusion Reactions</i>
2010	Blood Systems Research Institute weekly post-doc seminar; <i>Transfusion-Transmitted Babesiosis "Malaria hits New England"</i>
2010	Blood Systems Research Institute weekly summer intern presentation; <i>Blood Safety in Africa</i>
2010	American Osteopathic College of pathologists Fall CME conference; <i>Leukocyte Microchimerism Following Blood Transfusion</i>
2010	Kaiser Permanente Dept of Pediatrics; <i>Transfusion Reactions</i>
2010	California Blood Bank Society (Regional meeting, Sacramento); <i>Emerging Transfusion Transmitted Diseases</i>
2011	Medical and Scientific Advisory Committee meeting, Blood Centers of the Pacific; <i>A case of Transfusion-Transmitted Malaria</i>
2011	Technical Advisory committee meeting, Blood Centers of the Pacific; <i>Approach to platelet transfusion refractoriness</i>
2011	University of San Francisco, Theology and HIV course; <i>Blood Safety in Africa</i>
2011	America's Blood Centers, Fund Development, communications and Donor Recruitment Workshop <i>Blood safety in Africa, Clinical Practice and Research</i>
2011	North Inyo Hospital, Bishop, CA; <i>Bloodbanking in the Eastern Sierras :Indications, Risks and Challenges</i>
2011	UCSF Department of Laboratory Medicine (Resident core lecture series); <i>Beyond Blood banking: Overview of Blood substitutes, Blood Pharming, PRP, Universal red cells, PRP and autologous serum eye drops</i>
2011	Menlo Highschool, Atherton CA, Anatomy class; <i>Pathology in a nutshell</i>
2011	Cerus Corporation, Concord, CA; <i>Blood Safety in Africa: Organizational Challenges and Infectious Disease</i>
2011	Blood Systems TMAP teleconference; <i>B. microti Donor Screening and Follow-up Studies to Establish National Screening Policies</i>
2012	Menlo High school, Atherton CA, Anatomy class; <i>Pathology in a nutshell</i>
2013	UC Riverside Global Health Day; <i>Blood Safety in South Africa and Brazil</i>
2013	California Department of Public Health: Division of Communicable Disease Control; <i>Current Issues and Public Health Response Related to Blood-Transfusion Transmitted Disease</i>
2013	UCSF residents Transfusion Medicine Core curriculum; <i>Irradiated blood products and washed/volume reduced components</i>
2013	BSI Transfusion Medicine and Academic Policy meeting; <i>Transfusion Transmitted Babesiosis: the decision to screen blood donors for Babesia microti</i>
2013	University of San Francisco, Theology and HIV course; <i>Blood Safety in Africa</i>
2014	BSRI Transfusion Symposium; <i>Obstetric Blood Transfusion</i>

- 2014 South Central Association of Blood Banks annual meeting, Fort Worth TX, Karen Williams Memorial lecture; *Advances in Blood Safety*
- 2014 Creative Testing Solutions, Medical Scientific Advisory Board meeting, Scottsdale, AZ; *Update on Babesia studies*
- 2014 UCSF-Global Health Sciences-Masters Program, BSRI; *Blood Safety in Africa*
- 2014 Menlo High school, Atherton CA, Anatomy class; *Blood Banking, Pathology and Careers in Medicine*
- 2014 Roatán Interprofessional Program Symposium; *TIGRE-Transdisciplinary Immersion in Global Health research and Education*
- 2015 UCSF-Department of laboratory medicine; *Transfusion Transmitted Babesiosis: lessons learned from an emerging infectious disease*
- 2016 Johns Hopkins Borrelia Interest Group; *Babesia microti and the US Blood Supply, 31st March 2016*
- 2016 Johns Hopkins University Pathology Symposium, *Zika and the Blood Supply: Lessons Learned, 27th October 2016*
- 2017 Johns Hopkins University Fisher Center; *African BAOBAB (BAbesia OBServational AntiBody) Study, 3rd January, 2017*
- 2018 Johns Hopkins University Pathology Symposium, *Emerging infectious diseases and the Blood Supply, 25th October 2018*
- 2019 Regional American Red Cross Medical Advisory Committee, *Bacterial Contamination of Platelets: Challenges surrounding risk assessment and responsiveness, 8th January 2019*
- 2019 University of Maryland, 16th January 2019. *Emerging Infectious Diseases and the Blood Supply: Focus on Zika and Babesia microti*
- 2020 Grand Rounds Johns Hopkins University Dept of Pathology (webinar), *Deployment of convalescent plasma for the prevention and treatment of COVID-19, 27th April 2020*
- 2020 Johns Hopkins University Center for Global Health (webinar), *Use of convalescent plasma/ transfusions in Low and Middle-income countries (LMICs), 22nd May 2020*
- 2020 Maryland Department of Health. *Convalescent plasma for prevention and treatment of COVID-19 What and Why? 3rd June 2020.*
- 2020 Tufts Medical Center (Boston, MA). *Transfusion-Transmitted Infections: an overview, 23rd September 2020.*
- 2020 National Institutes of Health Department of Transfusion Medicine (presented virtually). *Convalescent plasma to prevent or treat COVID-19 lessons learned in a pandemic. 18th December 2020*
- 2021 Hematology Grand Rounds, Johns Hopkins University School of Medicine (Virtual) *Transfusion-transmitted Infections: A Brief History. 11 January 2021*
- 2021 Summer Institute, Tropical Medicine, Johns Hopkins Bloomberg School of Public Health *Transfusion-transmitted Infections: History, risk and intervention. 4 August 2021*
- 2022 Tufts Medical Center, Department of Pathology *Transfusion-transmitted Infections. 5 January 2022*
- National
- 2010 American Society of Clinical Pathology (ASCP); (audioconference); *Leukocyte Microchimerism Following Blood Transfusion*
- 2011 Tufts Medical Center, Dept of Pathology, Boston, MA; *Blood Safety in Africa*
- 2016 Lyme Disease Association/Columbia CME Conference, St. Paul, MN, *Babesia and the Blood Supply: Lessons Learned, 15th October 2016*
- 2017 HIV Prevention and Treatment Network, Annual Meeting Plenary; *Networking in the 21st Century: Responding to Emerging Infectious Diseases, 11th April 2017*
- 2018 Transfusion Medicine and Cellular Therapy, New York Presbyterian Hospital-Weill Cornell, New York; *Emerging infectious diseases and the Blood Supply, 13th June 2018*
- 2018 United States Food and Drug Administration (FDA); *Implementation of A secondary bacterial culture system to address residual risk of bacterial contamination of platelets, 18th July 2018*
- 2018 University of California San Francisco-Global Health Sciences *Master of Science in Global Health: 9 years on, 10th, 27th July 2018*
- 2019 AABB Webinar *Update on Testing for Emerging Transfusion-Transmitted Infections: Babesia, Zika & Dengue. 24th July 2019*
- 2019 National Institutes of health, 38th Annual Symposium Immunohematology and blood transfusion *Bacterial contamination of platelets. 19th September 2019*
- 2019 AABB Annual Meeting and TXPO, San Antonio, Tx. 20th October 2019 *Measures to mitigate residual risk from bacterial contamination of platelets: A hospital perspective.*

- 2020 American Society for Apheresis (webinar), *Convalescent plasma for COVID-19: Considerations for the Hospital*, 3rd April 2020
- 2020 American Society of Hematology (webinar), Convalescent plasma for prevention and treatment of COVID-19 A hospital perspective. 12th May 2020
- 2020 American Society for Apheresis (webinar), *Updates on the Use of COVID-19 Convalescent Plasma*, 12th June 2020
- 2020 Blood Banks Association of New York State (webinar), *Convalescent plasma as treatment of COVID-19: what we know so far*, 12th August 2020
- 2020 Society for the Advancement of Blood Management (webinar), *Use of Convalescent Plasma to prevent or treat COVID-19*, 11th September 2020 (pre-recorded 19 August 2020)
- 2020 American Society of Clinical Pathology (ASCP) annual meeting (webinar), DMT128-20 Bugs in Blood: Improving Transfusion Safety via the Detection or Elimination of Bacteria in Platelet Products *Bacterial contamination of platelets Overview of risk and mitigation with attention on secondary bacterial culture*, 9th September 2020 (pre-recorded 24 August 2020)
- 2020 Diabetes Technology Society, International COVID-19 and Diabetes Summit, 26-27th August 2020 (webinar), *Use of Convalescent Plasma to prevent or treat COVID-19: Evidence, Access and Research*, 26th August 2020
- 2020 North Carolina Association of Blood Bankers/South Central Association of Blood Banks, 15th September 2020 (webinar), *An old therapy for a new disease what have we learned about convalescent plasma in the COVID-19 pandemic?*
- 2020 AABB Annual Meeting and TXPO, Virtual, 3-5th October 2020
Vectors, protists and worms: What are the new threats to blood operators globally and how do they still impact North America? (Pre-recorded)
Outpatient studies of Convalescent Plasma to prevent or treat COVID-19 (Live 4th October 2020)
- 2020 American Society of Hematology [ASH] (Virtual) *Promise in Plasma? What is the Experience using Convalescent Plasma to Treat SARS-CoV-19?* 62nd ASH Annual Meeting & Exhibition, 6th December 2020
- 2020 Indian Country COVID-19 ECHO (Virtual) *Convalescent plasma to prevent or treat COVID-19 How, what and why?* 2nd December 2020
- 2021 UC Riverside Genetics, Genomics, and Bioinformatics Ph.D. program (Virtual) *Convalescent plasma to prevent or treat COVID-19: New insights for an old therapy*, 20 January 2021
- 2021 Washington University in St. Louis Laboratory and Genomic Medicine Grand Rounds, (Virtual) *Convalescent plasma to prevent or treat COVID-19: New insights for an old therapy*, 4 February 2021
- International
- 2009 REDS-III project planning meeting held at South African National Blood Service (SANBS) in Johannesburg, South Africa; (attendee and presenter); *Transfusion Associated Microchimerism in the Obstetric Population*
- 2010 University of Witwatersrand, Dept of Hematology and Molecular Medicine, Johannesburg, South Africa; *Leukocyte Microchimerism Following Blood Transfusion*
- 2010 Invited attendee Botswana National Transfusion Committee planning meeting for Policy and Clinical Guidelines; held in Gaborone, Botswana; funded by Safe Blood for Africa foundation
- 2010 Inkosi Albert Luthuli Hospital, Dept of Hematology, Durban, South Africa; *Leukocyte Microchimerism Following Blood Transfusion*
- 2010 University of Kwazulu-Natal, School of Public Health, Durban, South Africa; *Blood Safety in Africa*
- 2010 Dept of Obstetrics, King Edward VIII Hospital Durban, South Africa; *Management of Transfusion Reactions*
- 2010 Doris Duke medical research Institute, NR Mandela School of Medicine, Durban, South Africa; *Leukocyte Microchimerism Following Blood Transfusion; Introduction to REDS-III research program*
- 2010 Botswana National Transfusion Committee meeting for finalization of national Policy; Gaborone, Botswana; funded by Safe Blood for Africa foundation
- 2011 National Laboratory Medicine Congress, Sandton, South Africa; *Transfusion Associated Microchimerism: The Hybrid Within*
- 2013 Stakeholders Meeting, Kiev Ukraine; *International standards in Blood Banking*
- 2013 Post-graduate Diploma of Transfusion Medicine, University of the Free State, South Africa; *Blood Safety in Africa; Peripartum Blood Transfusion; Transfusion Associated Microchimerism; Transfusion Transmitted Babesiosis: the decision to screen blood donors for Babesia microti*
- 2013 South African National Blood Transfusion Congress, Cape Town, South Africa; *Peripartum blood transfusion in South Africa, a high HIV prevalence setting*

- 2014 Seguridad Sanguinea: Tendencias compromisos, éxito y retos, conference, PAHO and Grupo Cooperativo Iberoamericano de Medicina Transfusional, Lima, Peru; *Health Economics in a Nutshell: a Blood Banking Perspective*
- 2015 25th Regional Conference of ISBT, London, United Kingdom; *A prospective evaluation of chronic B. microti infection in seroreactive blood donors*
- 2015 South African National Blood Transfusion Congress, Drakensberg, South Africa; *REDS-III South Africa Obstetric Studies*
- 2016 IX Congreso Asociación Colombiano de Bancos de Sangre y Medicina Transfusional, Medellín, Colombia; *Transfusion transmitted babesiosis: Response to Emerging Infectious Diseases, a Blood Banking perspective; Advances in Blood Safety; REDS-III South Africa: Studies of Obstetric hemorrhage and Transfusion Practice*
- 2016 ISBT 34th International Congress Congress, Dubai, United Arab Emirates; *State of the Art in Obstetric Transfusion Practice: The REDS Programme*
- 2017 Segundo Seminario Internacional en Salud Enfermedades Infecciosas, Santa Cruz de la Sierra, Bolivia; *Zika y suministro de sangre: Lecciones aprendidas; Babesia: Una enfermedad infecciosa emergente*
- 2017 Africa Society of Blood Transfusion Meeting, Sun City, South Africa; *The Role of the Education Committee*
- 2017 ISBT Webinar; *Emerging Infectious Diseases and Blood Safety in the 21st Century*
- 2018 XVII Congreso Iberoamericano de Bancos de Sangre y Medicina Transfusional, Barranquilla, Colombia *Bacterial contamination of Blood Products: a Neglected Threat to the Blood Supply; Zika and the Blood Safety: a US Perspective*
- 2018 35th International congress of the ISBT, Toronto, Canada; *Update of activities of the ISBT Parasite sub group*
- 2018 Technical Advisory Group meeting, Tbilisi, Georgia, 30th November 2018. *Blood bank Assessments*
- 2018 Canadian Blood Services, 12th December 2018. *Emerging Infectious Diseases and the Blood Supply: Focus on Zika and Babesia microti*
- 2019 29th Regional Congress of the ISBT in Basel, Switzerland, 23rd June 2019; *A risk-based decision-making framework for blood safety: what's the case for Zika?*
- 2019 MU-JHU (Makarere University-Johns Hopkins University), Kampala, Uganda; *Blood Safety in Africa*; 9 September 2019
- 2019 Grifols Learning Academy (video webinar), *Transfusion transmitted parasites*; 25th September 2019
- 2020 Terumo BCT (webinar), *Convalescent plasma for COVID-19: Considerations for the Hospital*, 15th April 2020 [Latin America]
- 2020 Pathcast (webinar), *Convalescent plasma for prevention and treatment of COVID-19 an old hope for a new disease*, 30th April 2020
- 2020 International Society of Blood Transfusion (webinar), *Use of convalescent plasma / transfusions in Low and Middle-income countries (LMICs): A focus on donor-related challenges*, 22nd July 2020
- 2020 Convalescent plasma / Pathogen Reduction briefing, Permanent commission on health, Mexican senate Extraordinary commission on COVID-19, Mexican House & Senate (via virtual platform), *Use of Convalescent Plasma to prevent or treat COVID-19: Experience in the United States*, July 27, 2020.
- 2020 National CDC Georgia (invited presentation by zoom), *Blood Transfusion Safety in Georgia: The transition to a voluntary donor pool / not-for-profit model*, 2nd September 2020
- 2020 COVID-19 ECHO webinar. *Use of convalescent plasma to prevent and/or treat COVID-19: A mixed bag*. University of Cape Town, South Africa 7th October 2020
- 2020 Transfusion Medicine Summit for Latin America and Canada. *Use of convalescent plasma to prevent and/or treat COVID-19: A mixed bag*. Abbott Laboratories. 8th October 2020
- 2020 11th Congreso Colombiano 18th Congreso Iberoamericano de bancos de sangre y medicina transfusional, (via virtual platform), 8-11 October 2020
A current guide to patient blood management
A beginner's guide to Tissue banking
- 2020 All-Russian Conference (presented virtually). *Use of convalescent plasma for patients with COVID-19: what have we learned so far?* Moscow, Russia, 21st October 2020
- 2020 Scientific committee of HCV Elimination program, Georgia (presented virtually). NAT Pilot Study, 12th November 2020
- 2020 University of Toronto Transfusion Medicine Monthly Rounds (presented virtually). *Convalescent plasma to prevent or treat COVID-19 lessons learned in a pandemic*. Toronto, ON, Canada. 10th December 2020
- 2022 The 10th AfSBT International Congress. *The AABB Global Transfusion Forum: a collaborative, multifaceted blood safety initiative*. Senegal, 20 September 2022